Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.56 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESRRB | O95718 | 2/20 | 0.50 |
| ▸ | ESRRG | P62508 | 2/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305974 | 0.93 | USP2 (0.63) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL6369559 | 0.91 | USP2 (0.54) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4553154 | 0.91 | L3MBTL3 (0.57) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| Hydrochloric Acid SCHEMBL6132979 | 0.90 | USP2 (0.52) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL6135887 | 0.87 | L3MBTL3 (0.51) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL15951981 | 0.87 | L3MBTL3 (0.73) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL4123114 | 0.87 | HRH3 (0.56) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL6125963 | 0.86 | USP2 (0.51) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL13006657 | 0.86 | ALDH1A1 (0.58) | MEN1KMT2AHRH3ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL723578 | 0.86 | L3MBTL3 (0.67) | USP2L3MBTL3L3MBTL1MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877927-B2 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors | GRUNENTHAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| CN-101511841-B | Tetrahydrofuro [3,2-B ] pyrrol-3-ones as cathepsin K inhibitors | AMURA THERAPEUTICS LTD | 2013-08-07 | — | — | CN | disclosed |
| EP-2044075-B1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LTD (GB) | 2013-01-02 | — | — | EP | disclosed |
| EP-2046796-B1 | TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| EP-2046795-B1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-2046797-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| EP-2046798-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-7846934-B2 | Furo[3,2-B] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-7846935-B2 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| CN-101511841-A | Tetrahydrofuro [3, 2-B ] pyrrol-3-ones as cathepsin K inhibitors | ARMURA THERAPEUTICS LTD (GB) | 2009-08-19 | — | — | CN | disclosed |
| US-20090203714-A1 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| EP-2046796-A1 | TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | Amura Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046797-A1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | Amura Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008007127-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007114-A1 | TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007112-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | CTSS, CTSK, TMPRSS6 | USP2 4539/4885L3MBTL3 774/4885L3MBTL1 1407/4885 |
| US-20090192170-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | COLGALT1, COL2A1, ABCB1 | USP2 4247/4885L3MBTL3 3879/4885L3MBTL1 3254/4885 |
| US-20090203714-A1 | Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors | CTSB, CTSS, CTSL | USP2 3762/4885L3MBTL3 3054/4885L3MBTL1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.